These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 9490274

  • 1. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
    Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA.
    Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
    Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, Bartelink H, Verheij M.
    Radiother Oncol; 2001 Nov; 61(2):169-75. PubMed ID: 11690683
    [Abstract] [Full Text] [Related]

  • 6. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
    Uchida T, Minei S, Gao JP, Wang C, Satoh T, Baba S.
    Oncol Rep; 2002 Nov; 9(2):253-9. PubMed ID: 11836589
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas A, Dimopoulos C.
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [Abstract] [Full Text] [Related]

  • 9. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium.
    Bilim VN, Tomita Y, Kawasaki T, Takeda M, Takahashi K.
    Cancer Lett; 1998 Jun 05; 128(1):87-92. PubMed ID: 9652797
    [Abstract] [Full Text] [Related]

  • 10. [Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage].
    San Miguel Fraile P, Antón Badiola I, Ortiz Rey JA, Alvarez Alvarez C, Fernández Costas A, Lago Fernández M, Pelaez Boismorand E, Zungri Telo E, De La Fuente Buceta A.
    Actas Urol Esp; 2003 Sep 05; 27(8):587-93. PubMed ID: 14587233
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Finnbladder III Group.
    Liukkonen TJ, Lipponen PK, Helle M, Jauhiainen KE.
    Urol Res; 1997 Sep 05; 25(1):1-7. PubMed ID: 9079739
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder.
    Kilicli-Camur N, Kilicaslan I, Gulluoglu MG, Esen T, Uysal V.
    Pathol Int; 2002 Jul 05; 52(7):463-9. PubMed ID: 12167105
    [Abstract] [Full Text] [Related]

  • 15. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A, Posch B, El-Baz M, Mokhtar AA, Susani M, Ghoneim MA, Marberger M.
    J Urol; 2001 May 05; 165(5):1481-7. PubMed ID: 11342901
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A, Kausch I, Feller AC, Krüger S.
    Oncol Rep; 2005 Oct 05; 14(4):1065-70. PubMed ID: 16142373
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.